Compare · NVO vs PBYI
NVO vs PBYI
Side-by-side comparison of Novo Nordisk A/S (NVO) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 513.2x PBYI ($434.2M).
- Over the past year, NVO is down 21.8% and PBYI is up 150.7% - PBYI leads by 172.5 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 4 for PBYI).
- Company
- Novo Nordisk A/S
- Puma Biotechnology Inc
- Price
- $50.31-2.25%
- $8.53+1.25%
- Market cap
- $222.81B
- $434.2M
- 1M return
- +15.47%
- +18.73%
- 1Y return
- -21.78%
- +150.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 4
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PBYI
- President and CEO Auerbach Alan H sold $364,051 worth of shares (44,058 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 0.60% to 7,261,671 units (SEC Form 4)
- Officer Hunt Douglas M sold $69,905 worth of shares (8,460 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 196,841 units (SEC Form 4)
- Chief Financial Officer Nougues Maximo F sold $77,557 worth of shares (9,386 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 230,637 units (SEC Form 4)
- SEC Form 144 filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wilson Troy Edward was granted 27,000 shares and sold $77,748 worth of shares (10,800 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 59,750 units (SEC Form 4)
- Director Stuglik Brian M was granted 27,000 shares and sold $58,311 worth of shares (8,100 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 113,858 units (SEC Form 4)
- Director Senderowicz Adrian sold $194,311 worth of shares (27,000 units at $7.20) as part of a pre-agreed trading plan and was granted 27,000 shares (SEC Form 4)
- Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)